Jefferies downgraded Staar Surgical (STAA) to Hold from Buy with a price target of $18, down from $60, following the company’s Q4 report and initial 2025 guidance. The outlook reflects a challenging first half and a wide range for the second half recovery that is dependent on the China refractive market declining 10% to growing 10%, which “doesn’t inspire much confidence,” the analyst tells investors. The Q4 updates showed lack of visibility with its China distributors sell throughs, raising “more questions which will take some time” for investors to digest and for Staar to resolve, the analyst says.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical downgraded to Hold from Buy at Jefferies
- Tesla, Instacart initiated: Wall Street’s top analyst calls
- Hold Rating on Staar Surgical Amidst Revenue Challenges in China and Cautious Optimism for US Growth
- Staar Surgical price target lowered to $16 from $40 at Piper Sandler
- Staar Surgical Faces Challenges Amidst Significant Decline in Chinese Market Sales, Prompting Sell Rating